About

Tahir Zaman, MD, is a Clinical Instructor of Medicine at the University of Utah School of Medicine. He received his Bachelor of Science from Washington State University in 2006 and his medical degree from the University of Washington School of Medicine in 2010. Dr. Zaman completed his Internal Medicine training at the University of Utah in 2013 and served as a Chief Medical Resident until 2014. He then specialized further in Nephrology, completing his subspecialty training in 2016. Since joining the University of Utah Wasatch Kidney Specialists in 2016, he has been practicing Clinical Nephrology, with his main office at St. Mark’s Hospital. His clinical interests include chronic kidney disease, hypertension, kidney stones, polycystic kidney disease, hemodialysis, peritoneal dialysis, and kidney transplant care. Dr. Zaman is board-certified by the American Board of Internal Medicine with a subspecialty certification in Nephrology, and he actively contributes to patient care at various clinical locations, including outreach clinics in South Jordan and Tooele.

Research topics

• Medicine
• Radiology
• Cardiology
• Internal medicine
• Pathology

Selected publications

• Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review

  Cureus · 2024-11-14 · 2 citations

  reviewOpen accessSenior author

  Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a promising class of medications for type 2 diabetes (T2D) management. While their glucose-lowering effects are well-established, their long-term impact on cardiovascular outcomes remains a subject of ongoing research and debate. This systematic review aims to assess the long-term cardiovascular effects of GLP-1 RAs in adults with T2D compared to placebo, standard care, or other glucose-lowering medications. We systematically searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) and observational studies published from database inception to April 2024. Two independent reviewers screened the studies and extracted the data. The primary outcome was major adverse cardiovascular events (MACE), a composite of cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke. Secondary outcomes included individual components of MACE, hospitalization for heart failure, and all-cause mortality. We included 15 studies (eight RCTs and seven observational studies) involving over 180,000 participants. GLP-1 RAs were associated with a significant reduction in MACE compared to placebo or standard care (risk ratio: 0.88, 95% CI: 0.82-0.94, p<0.001). GLP-1 RAs also demonstrated superior cardiovascular protection compared to DPP-4 inhibitors and sulfonylureas. The benefits were particularly pronounced in reducing the risk of stroke and MI. Notably, some studies found larger cardiovascular benefits in frail patients. The effects on heart failure outcomes were mixed, with potential attenuated benefits in patients with baseline heart failure. GLP-1 RAs also showed promising effects on renal outcomes and metabolic parameters. The quality of evidence ranged from moderate to high across outcomes. This systematic review provides strong evidence that GLP-1 RAs offer significant cardiovascular benefits in adults with T2D, particularly in reducing MACE, stroke, and MI. The findings support current guidelines recommending GLP-1 RAs as preferred agents in patients with established cardiovascular disease or high cardiovascular risk. However, the variability in effects across different patient subgroups underscores the need for personalized treatment approaches. Future research should focus on head-to-head comparisons between different GLP-1 RAs, long-term follow-up studies, and investigation of combination therapies to further optimize the use of these agents in clinical practice.

  PublisherOA PDFDOI

• Effects of Oil Contamination on the Geotechnical Properties of Clayey Soil

  Journal of ICT Design Engineering and Technological Science · 2022-01-01 · 2 citations

  articleOpen accessSenior author

  The leakage of oil products which results in making the soil pollute or impure and alter its physical and mechanical properties due to the presence of hydrocarbons in it. Those hydrocarbons which cannot be passed into soil through the pores and become congest on top of the land. Hence it is necessary to indicate and know the geotechnical properties of the contaminated soil. Recently the modern technique is an encompassing laboratorial system intends to encourage and improve the high level of determining the effects of Oil contaminants on the geotechnical properties of the soil. In this way, the laboratory indications containing the fundamental properties like Atterberg limitations, direct shear, sieve analysis and unconfined compression has been taken from the contaminated soil. The contaminated samples were taken from two different areas of each site containing surface and 1m deep samples which shows the different substantial kinds of variances in the soil consequences after contamination occur in it.

  PublisherOA PDFDOI

• COVID-Related Renal Thrombotic Microangiopathy: Role of Plasma Exchange

  Journal of the American Society of Nephrology · 2021-10-01

  article

  Introduction: The most common COVID-19 associated glomerular diseases are COVID associated nephropathy (COVAN) and Thrombotic Microangiopathy (TMA). Other less common glomerular diseases associated with COVID reported are antineutrophil cytoplasmic antibody (ANCA) vasculitis, anti-glomerular basement membrane (Anti GBM) antibody disease, podocytopathies, and IgA nephropathy. We report a case of TMA due to COVID-19 infection. Case Description: A 67-year-old woman with asthma was admitted for COVID related respiratory failure and was noted to have acute kidney injury with anemia and thrombocytopenia. She was hypertensive and urine analysis was notable for hematuria and proteinuria. ANA, ANCA, Anti GBM, Coombs, ADAMTS13, disseminated intravascular coagulation panel, serum immune fixation and free light chains, cryoglobulins, and infectious work up were unrevealing. Complement C3 and C4 were low, lactate dehydrogenase and bilirubin were high, haptoglobin was undetectable, and schistocytes were seen on peripheral smear which raised concern for thrombotic microangiopathy. Renal function deteriorated rapidly with ensuing anuria prompting initiation of dialysis. Kidney biopsy confirmed acute thrombotic microangiopathy. She was started on plasma exchange (PLEX) for COVID related thrombotic microangiopathy and she started producing urine with rapid improvement in creatinine (Cr) after two treatments. Cr was down to 3.11mg/dL from a peak of 7.45 mg/dL after PLEX and normalized at discharge. The patient is currently being monitored with renal panel and complete blood picture every three months, as an outpatient. Discussion: COVID is known to cause TMA that is presumed to be secondary to endothelial dysfunction and complement activation. There are no standard guidelines for treatment. Terminal complement blockade was not used in our patient. Our case demonstrates the efficacy of PLEX in the treatment of COVID related TMA. Early recognition and treatment is crucial and may reduce morbidity and mortality.

  PublisherDOI

• Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure

  American Journal of Kidney Diseases · 2021 · 4 citations

  • Medicine
  • Internal medicine
  • Cardiology
  DOI

• Safety of elective paediatric surgery during the coronavirus disease 2019 pandemic

  International Journal of Pediatric Otorhinolaryngology · 2021-08-08 · 4 citations

  articleOpen access
  PublisherOA PDFDOI

• Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease

  JAMA Neurology · 2021 · 69 citations

  • Medicine
  • Internal medicine
  • Cardiology

  Importance: Meta-analyses of randomized clinical trials have indicated that improved hypertension control reduces the risk for cognitive impairment and dementia. However, it is unclear to what extent pathways reflective of Alzheimer disease (AD) pathology are affected by hypertension control. Objective: To evaluate the association of intensive blood pressure control on AD-related brain biomarkers. Design, Setting, and Participants: This is a substudy of the Systolic Blood Pressure Intervention Trial (SPRINT MIND), a multicenter randomized clinical trial that compared the efficacy of 2 different blood pressure-lowering strategies. Potential participants (n = 1267) 50 years or older with hypertension and without a history of diabetes or stroke were approached for a brain magnetic resonance imaging (MRI) study. Of these, 205 participants were deemed ineligible and 269 did not agree to participate; 673 and 454 participants completed brain MRI at baseline and at 4-year follow-up, respectively; the final follow-up date was July 1, 2016. Analysis began September 2019 and ended November 2020. Interventions: Participants were randomized to either a systolic blood pressure goal of less than 120 mm Hg (intensive treatment: n = 356) or less than 140 mm Hg (standard treatment: n = 317). Main Outcomes and Measures: Changes in hippocampal volume, measures of AD regional atrophy, posterior cingulate cerebral blood flow, and mean fractional anisotropy in the cingulum bundle. Results: Among 673 recruited patients who had baseline MRI (mean [SD] age, 67.3 [8.2] years; 271 women [40.3%]), 454 completed the follow-up MRI at a median (interquartile range) of 3.98 (3.7-4.1) years after randomization. In the intensive treatment group, mean hippocampal volume decreased from 7.45 cm3 to 7.39 cm3 (difference, -0.06 cm3; 95% CI, -0.08 to -0.04) vs a decrease from 7.48 cm3 to 7.46 cm3 (difference, -0.02 cm3; 95% CI, -0.05 to -0.003) in the standard treatment group (between-group difference in change, -0.033 cm3; 95% CI, -0.062 to -0.003; P = .03). There were no significant treatment group differences for measures of AD regional atrophy, cerebral blood flow, or mean fractional anisotropy. Conclusions and Relevance: Intensive treatment was associated with a small but statistically significant greater decrease in hippocampal volume compared with standard treatment, consistent with the observation that intensive treatment is associated with greater decreases in total brain volume. However, intensive treatment was not associated with changes in any of the other MRI biomarkers of AD compared with standard treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT01206062.

  DOI

• Illness Perceptions, Perceived Social Support and Quality of Life in Patients of End Stage Renal Disease

  2018-01-01

  article1st authorCorresponding

  Objective. The purposive of the current research was to assess the relationship between illness perceptions, perceived social support and quality of life in patients with end stage of renal disease.  Design. Co-relational research design was used. Place and Duration of Study. This study was conducted at Allied Hospital Lahore and was completed within six months. Methods. The data was collected via survey method using purposive sampling. Illness perceptions, perceived social support and quality of life were assessed using relevant standardized tools.  Result. The results postulated that there is a strong relationship between illness perceptions, perceived social support and quality of life. Moreover, illness perceptions and perceived social support significantly positively predicted quality of life in patients with end stage renal disease. Conclusions.  The results from this empirical research highlighted that quality of life is predicted by illness perceptions and perceived social support in patients with end stage renal disease.

  Publisher

• Implications and Importance of Skeletal Muscle Mass in Estimating Glomerular Filtration Rate at Dialysis Initiation

  Journal of Renal Nutrition · 2013-04-22 · 28 citations

  review1st author
  PublisherDOI

Frequent coauthors

• Srinivasan Beddhu

  VA Salt Lake City Healthcare System

  58 shared

• Daniel E. Weiner

  Tufts Medical Center

  38 shared

• Dan R. Berlowitz

  27 shared

• Peter Van Buren

  The University of Texas Southwestern Medical Center

  27 shared

• Clive Rosendorff

  Sprint (United States)

  27 shared

• Addison A. Taylor

  Virginia Commonwealth University

  27 shared

• R. Nick Bryan

  University of Pennsylvania

  26 shared

• Nicholas M. Pajewski

  Wake Forest University

  18 shared